– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment
– Data are featured in the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting 2023
– Incyte and its partner Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023
Incyte (NASDAQ:INCY) and Syndax Pharmaceuticals (NASDAQ:SNDX) today announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. These data are featured today in the Plenary Scientific Session (Abstract #1) at the 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually.
